Full-Time

Director

Deadline 12/4/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$178.5k - $257.8k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

Hybrid

Hybrid role based in Cambridge or Morristown, with approximately 20–30% travel.

Bachelor's, MBA

Category
Customer Experience & Support (2)
,
Required Skills
Market Research
Branding/Brand Strategy
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A Bachelor's Degree is required.
  • A minimum of 7 years of pharmaceutical, biotechnology, or specialty pharmacy experience is required.
  • Demonstrated ability to strategically design patient support programs aligned to brand and corporate objectives is required.
  • Strong understanding of legal and regulatory parameters governing patient support programs in the pharmaceutical industry is required.
  • A proven track record leading product launches or major strategic initiatives in a matrixed environment, including budget management, is required.
  • Experience driving digital innovation and operational excellence in patient services or healthcare operations is required.
  • Strong analytical skills to evaluate trends and identify program improvement opportunities are required.
  • The ability to build relationships and resolve conflict is required.
  • The ability to travel approximately 20–30% is required.
Responsibilities
  • Own the strategic design of the Alpha-1 Antitrypsin Deficiency Patient Support Program, including the service model, staffing plan, key performance indicators, and operating structure.
  • Lead launch readiness across the Patient Support Services remit and translate strategy into an operating capability ready on day one.
  • Represent Alpha-1 Antitrypsin Deficiency Patient Support Services as the launch lead in cross-functional forums and leadership reviews.
  • Drive innovation in program design and explore new partnership models to enhance patient access and experience.
  • Own ongoing operational performance of the Alpha-1 Antitrypsin Deficiency Patient Support Services program by monitoring key performance indicators, budget, and service levels and course-correcting as needed.
  • Partner with the Head of Rare Disease Patient Support Services to align Field Education and Case Management teams to the Rare Go-to-Market model and prepare them to support Alpha-1 Antitrypsin Deficiency patients.
  • Drive the end-to-end digital experience and operational excellence by working with Patient Support Services Centers of Excellence on innovation, automation, and best practices.
  • Use data, insights, and stakeholder feedback to assess program performance and identify enhancement opportunities.
  • Lead vendor strategy, performance, and quality oversight for financial assistance, copay, access technology, and market research vendors, including identifying partners and ensuring delivery against contracted service-level agreements.
  • Establish innovative partnerships with external organizations to enhance patient support capabilities and access solutions.
  • Own budget management for Alpha-1 Antitrypsin Deficiency Patient Support Services programs and operations.
  • Coordinate Alpha-1 Antitrypsin Deficiency patient-services matters across Commercial, Medical Affairs, Market Access, Legal, and Compliance.
  • Build relationships with healthcare providers, patient advocacy organizations, specialty pharmacies, and payers.
  • Partner with field access and field education leaders to provide a seamless disease-state and treatment experience.
  • Develop expertise in the Alpha-1 Antitrypsin Deficiency patient journey, treatment landscape, reimbursement pathways, and access barriers.
  • Monitor market, competitive, and regulatory developments and translate insights into operational and program adjustments.
  • Ensure compliance with corporate and industry policies and regulatory requirements governing patient support programs.
  • Define and report program critical success factors, key performance indicators, and standard operating procedures to leadership committees.
Desired Qualifications
  • An MBA or advanced degree is preferred.
  • Prior leadership experience building a function or program from the ground up is strongly preferred.
  • Direct experience with rare disease launches or patient support program development is preferred.
  • Experience in respiratory disease, pulmonology, or the Alpha-1 Antitrypsin Deficiency therapeutic area is preferred.
  • A background in case management, patient services, or healthcare operations is preferred.
  • Experience partnering with Patient Support Services Centers of Excellence or shared service models is preferred.
  • Established relationships within Alpha-1 Antitrypsin Deficiency patient advocacy and provider communities are preferred.
  • A track record of implementing digital tools or automation to enhance patient experience is preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.